Covaxin: India’s first Covid19 vaccine candidate.

Covaxin: India’s first Covid19 vaccine candidate.

India’s first Covid19 vaccine candidate, ‘Covaxin’ is developed by Bharat Biotech India Ltd (BBIL). The BBIL developed the vaccine in collaboration with the National Institute of Virology. Amid the rising coronavirus cases hundreds of candidates globally are trying their best to develop the vaccine. India has finally joined the race with other countries to develop Covid19 vaccine.

Covaxin is India’s first Covid19 vaccine candidate to get a nod for human trials. India is a leading manufacturer of vaccines and generic medicines. India can play a key role in this race as several Indian institutes are working on developing the vaccine.

What is Covaxin?

Covaxin is a potential Covid19 vaccine from India which is going for human trials. The Central Drugs Standard Control Organisation (CDSCO) has given its nod to BBIL to conduct human trials of Covaxin. The Drug Controller General of India (DCGI), which heads CDSCO has approved for phase I and phase II human clinical trials. The trial for Covaxin will begin in July across the country.

“We are proud to announce COVAXIN, India’s first indigenous vaccine against COVID-19. The collaboration with ICMR and NIV was instrumental in the development of this vaccine. Our R&D and Manufacturing teams worked tirelessly to deploy our proprietary technologies towards this platform,” says MD and Chairman of BBIL, Dr. Krishna Ella.

The Making of Covaxin.

Covaxin is an indigenous and inactivated vaccine developed at Hyderabad based Bharat Biotechs BSL-3 high containment facility. At first, the National Institute of Virology isolated a strain of novel coronavirus from an asymptomatic patient. Then early in May, the isolated strain was transferred to Bharat Biotechs in Hyderabad. 

Bharat Biotechs took Covaxin for pre-clinical trials on animals such as guinea pigs and mice to check if it is safe or not. Then the Hyderabad-based firm approached CDSCO for approval to move on to human trials. During the pre-clinical testing Covaxin has shown promising extensive safety and effective immune responses.

“Once we inject the vaccine into a human, it has no potential to infect or replicate, since it is a killed virus. It just serves the immune system as a dead virus and mounts an antibody response towards the virus,” says BBIL.

Other vaccine candidates.

The entire world is tirelessly working on developing a vaccine to fight Covid19. Scientists and researchers are working day and night to find an effective solution for this invisible enemy. Several big companies are putting their efforts due to which many vaccine candidates are in different stages of trial. 

AstraZeneca, the British firm is leading the vaccine race according to the World Health Organisation. It has already begun the mid-stage human trials at a large scale. The researchers of University of Oxford are the developers of AstraZeneca vaccine. The other most promising vaccine candidate is the one from American firm Moderna. Moderna will begin its phase III clinical trials from mid-July.

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.